Influence of Rifamycin on Survival in Patients with Concomitant Lung Cancer and Pulmonary Tuberculosis
Background: The coexistence of lung cancer and tuberculosis is not rare. Rifamycin plays a pivotal role in anti-tuberculosis therapy. However, its potential impact on the liver metabolism of oncology drugs raises concerns. We performed this study to explore whether Rifamycin affects the survival of...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/12/3130 |
| _version_ | 1827575523388162048 |
|---|---|
| author | Ho-Sheng Lee Yu-Feng Wei Chin-Chung Shu |
| author_facet | Ho-Sheng Lee Yu-Feng Wei Chin-Chung Shu |
| author_sort | Ho-Sheng Lee |
| collection | DOAJ |
| description | Background: The coexistence of lung cancer and tuberculosis is not rare. Rifamycin plays a pivotal role in anti-tuberculosis therapy. However, its potential impact on the liver metabolism of oncology drugs raises concerns. We performed this study to explore whether Rifamycin affects the survival of patients with tuberculosis and lung cancer. Methods: Drawing from the Taiwan National Health Insurance Research Database, we identified patients diagnosed with concurrent lung cancer and tuberculosis between 2000 and 2014. Patients were categorized based on whether they underwent rifamycin-inclusive or rifamycin-exempt anti-tuberculosis therapy. Subsequently, we paired them at a 1:1 ratio and evaluated the mortality risk over a two-year span. Results: Out of the study participants, 1558 (81.4%) received rifamycin-based anti-tuberculosis therapy, while 356 (18.6%) underwent a rifamycin-free regimen. Analysis revealed no marked variance in the biennial mortality rate between the groups (adjusted hazard ratio: 1.33, 95% confidence interval 0.93–1.90, <i>p</i> = 0.1238). When focusing on the matched sets comprising 127 individuals in each group, the data did not indicate a significant link between rifamycin and a heightened two-year mortality risk (adjusted hazard ratio: 1.00, 95% confidence interval 0.86–1.18, <i>p</i> = 0.9538). Conclusions: For individuals with concomitant lung cancer and tuberculosis, rifamycin’s administration did not adversely influence two-year survival. Thus, rifamycin-containing anti-TB regimens should be prescribed for the indicated patients. |
| first_indexed | 2024-03-08T20:58:18Z |
| format | Article |
| id | doaj.art-00c62150a23d45be9d5412c37fddb78c |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-08T20:58:18Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-00c62150a23d45be9d5412c37fddb78c2023-12-22T13:54:44ZengMDPI AGBiomedicines2227-90592023-11-011112313010.3390/biomedicines11123130Influence of Rifamycin on Survival in Patients with Concomitant Lung Cancer and Pulmonary TuberculosisHo-Sheng Lee0Yu-Feng Wei1Chin-Chung Shu2Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung 82445, TaiwanSchool of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung 82445, TaiwanDepartment of Internal Medicine, National Taiwan University Hospital, No. 7, Chung Shan South Road, Taipei 100225, TaiwanBackground: The coexistence of lung cancer and tuberculosis is not rare. Rifamycin plays a pivotal role in anti-tuberculosis therapy. However, its potential impact on the liver metabolism of oncology drugs raises concerns. We performed this study to explore whether Rifamycin affects the survival of patients with tuberculosis and lung cancer. Methods: Drawing from the Taiwan National Health Insurance Research Database, we identified patients diagnosed with concurrent lung cancer and tuberculosis between 2000 and 2014. Patients were categorized based on whether they underwent rifamycin-inclusive or rifamycin-exempt anti-tuberculosis therapy. Subsequently, we paired them at a 1:1 ratio and evaluated the mortality risk over a two-year span. Results: Out of the study participants, 1558 (81.4%) received rifamycin-based anti-tuberculosis therapy, while 356 (18.6%) underwent a rifamycin-free regimen. Analysis revealed no marked variance in the biennial mortality rate between the groups (adjusted hazard ratio: 1.33, 95% confidence interval 0.93–1.90, <i>p</i> = 0.1238). When focusing on the matched sets comprising 127 individuals in each group, the data did not indicate a significant link between rifamycin and a heightened two-year mortality risk (adjusted hazard ratio: 1.00, 95% confidence interval 0.86–1.18, <i>p</i> = 0.9538). Conclusions: For individuals with concomitant lung cancer and tuberculosis, rifamycin’s administration did not adversely influence two-year survival. Thus, rifamycin-containing anti-TB regimens should be prescribed for the indicated patients.https://www.mdpi.com/2227-9059/11/12/3130rifamycintuberculosislung cancersurvival |
| spellingShingle | Ho-Sheng Lee Yu-Feng Wei Chin-Chung Shu Influence of Rifamycin on Survival in Patients with Concomitant Lung Cancer and Pulmonary Tuberculosis Biomedicines rifamycin tuberculosis lung cancer survival |
| title | Influence of Rifamycin on Survival in Patients with Concomitant Lung Cancer and Pulmonary Tuberculosis |
| title_full | Influence of Rifamycin on Survival in Patients with Concomitant Lung Cancer and Pulmonary Tuberculosis |
| title_fullStr | Influence of Rifamycin on Survival in Patients with Concomitant Lung Cancer and Pulmonary Tuberculosis |
| title_full_unstemmed | Influence of Rifamycin on Survival in Patients with Concomitant Lung Cancer and Pulmonary Tuberculosis |
| title_short | Influence of Rifamycin on Survival in Patients with Concomitant Lung Cancer and Pulmonary Tuberculosis |
| title_sort | influence of rifamycin on survival in patients with concomitant lung cancer and pulmonary tuberculosis |
| topic | rifamycin tuberculosis lung cancer survival |
| url | https://www.mdpi.com/2227-9059/11/12/3130 |
| work_keys_str_mv | AT hoshenglee influenceofrifamycinonsurvivalinpatientswithconcomitantlungcancerandpulmonarytuberculosis AT yufengwei influenceofrifamycinonsurvivalinpatientswithconcomitantlungcancerandpulmonarytuberculosis AT chinchungshu influenceofrifamycinonsurvivalinpatientswithconcomitantlungcancerandpulmonarytuberculosis |